Cost–effectiveness of treatments for Alzheimer’s dementia

References

• Wimo A, Jonsson L, Winblad B. An estimate of the worldwide pevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord.21(3), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord.17, 63–67 (2003).
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet366(9503), 2112–2117 (2005).
   PubMed Web of Science ®Google Scholar
• SBU. Dementia. Stockholm, Sweden (report): SBU (The Swedish Council on Technology Assessment in Health Care) (2007) (In Press).
   Google Scholar
• Birks J, Grimley-Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease (Cochrane review). Oxford: The Cochrane Library, Report No.: Issue 2 (2003).
   Google Scholar
• Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). Oxford: The Cochrane Library; Report No.: Issue 2 (2003).
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer’s disease (Cochrane Review). Oxford: The Cochrane Library; Report No.: Issue 2 (2003).
   Google Scholar
• Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia: The Cochrane collaboration (2006).
   Google Scholar
• Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease. Cell Mol. Life Sci.63(13), 1538–1552 (2006).
   PubMedGoogle Scholar
• Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363(9427), 2105–2015 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider LS. AD2000: donepezil in Alzheimer’s disease. Lancet363(9427), 2100–2101 (2004).
   PubMed Web of Science ®Google Scholar
• Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. Lancet364(9441), 1213–1214 (2004).
   PubMedGoogle Scholar
• Day M. NICE says anti-dementia drugs should be used only for moderate Alzheimer’s disease Br. Med. J.333(7572), 774 (2006).
   PubMedGoogle Scholar
• Lanska DJ. Time is money – or is it? Estimating the costs of informal caregiving. Neurology58(12), 1718–1719 (2002).
   PubMed Web of Science ®Google Scholar
• McDaid D. Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry16(4), 400–405 (2001).
   PubMed Web of Science ®Google Scholar
• Wimo A, Wallin JO, Lundgren K et al. Impact of day care on dementia patients – costs, well-being and relatives’ views. Fam. Pract.7(4), 279–287 (1990).
   PubMed Web of Science ®Google Scholar
• Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. Pharmacoeconomics11(2), 159–168 (1997).
   PubMed Web of Science ®Google Scholar
• Gafni A. Alternatives to the QALY measure for economic evaluations. Support Care Cancer5(2), 105–111 (1997).
   PubMedGoogle Scholar
• Dolan P. A note on QALYs versus HYEs. Health states versus health profiles. Int. J. Technol. Assess. Health Care16(4), 1220–1224 (2000).
   PubMedGoogle Scholar
• Essink-Bot ML, Pereira J, Packer C, Schwarzinger M, Burstrom K. Cross-national comparability of burden of disease estimates: the European Disability Weights Project. Bull. World Health Organ.80(8), 644–652 (2002).
   PubMedGoogle Scholar
• Sassi F, McDaid D. Transnational analysis of the socio-economic impact of Alzheimer’s Disease (AD) in the European Union. London: London School of Economics, Report No.: European Commission: Contract No: SOC96 202099 05F02 (96CVVF3–415) (1999).
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res.12(3), 189–198 (1975).
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jonsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ.5(4), 279–296 (1996).
   PubMed Web of Science ®Google Scholar
• Karlsson G, Jonsson B, Wimo A, Winblad B. Methodological issues in health economics of dementia. Wimo A, Jonsson B, Karlsson G, Winblad B, (Eds). John Wiley & Sons, London, UK, In: Health economics of dementia, 161–169 (1998).
   Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ.6(3), 217–227 (1997).
   PubMed Web of Science ®Google Scholar
• SBU. Demenssjukdomar. En systematisk litteraturöversikt. Stockholm: SBU (2006).
   Google Scholar
• Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G et al. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord.15(1), 44–54 (2003).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology63(4), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics21(5), 327–340 (2003).
   PubMed Web of Science ®Google Scholar
• Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer’s disease. A modelling approach. Pharmacoeconomics16(2), 165–174 (1999).
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics17(4), 351–360 (2000).
   PubMed Web of Science ®Google Scholar
• Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Assessment of Health Economics in Alzheimer’s Disease (AHEAD). Treatment with Galantamine in Sweden. Pharmacoeconomics:20(9), 629–637 (2002).
   PubMed Web of Science ®Google Scholar
• François C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine on moderately severe to severe Alzheimer’s disease. A Markov model in Finland. Clin. Drug Invest.24(7), 373–384 (2004).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology52(6), 1138–1145 (1999).
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dement. Geriatr. Cogn. Disord.13(1), 33–39 (2002).
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmine. Clin. Ther.22(4), 439–451 (2000).
   PubMed Web of Science ®Google Scholar
• Loveman E, Green C, Kirby J et al. The clinical and cost–effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer’s disease. Southhampton: Health Technology Assessment NHS R&D HTA Programme; (2006.) Report No.;10, 1 (2006).
   Google Scholar
• Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. Br. Med. J.319(7210), 635–638 (1999).
   PubMed Web of Science ®Google Scholar
• Läkemedelsverket. Farmakologisk behandling av kognitiv störning vid Alzheimer’s sjukdom (pharmacological treatment of cognitive impairment in Alzheimer´s disease): Läkemedelsverket (Medical Products Agency); (2002.) Report No.: Information från läkemedelsverket, nr 7–8 (2002).
   Google Scholar
• Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer’s disease. Med. Interface7(10), 130–138 (1994).
   PubMedGoogle Scholar
• Henke CJ, Burchmore MJ. The economic impact of the tacrine in the treatment of Alzheimer’s disease. Clin. Ther.19(2), 330–345 (1997).
   PubMed Web of Science ®Google Scholar
• Wimo A, Karlsson G, Nordberg A, Winblad B. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis. Assoc. Disord.11(4), 191–200 (1997).
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Goeree R, Hux M et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J. Am. Geriatr. Soc.47(5), 570–578 (1999).
   PubMed Web of Science ®Google Scholar
• Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin. Ther.21(7), 1230–1240 (1999).
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology57(6), 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement. Geriatr. Cogn. Disord.14(2), 84–89 (2002).
   PubMed Web of Science ®Google Scholar
• Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United States. Clin. Ther.25(6), 1806–1825 (2003).
   PubMed Web of Science ®Google Scholar
• Jones RW, McCrone P, Guilhaume C. Cost–effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging21(9), 607–620 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int. J. Geriatr. Psychiatry13(7), 445–453 (1998).
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Getsios D, Ishak K, O’Brien J, Bullock R. Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UK. Int. J. Geriatr. Psychiatry;18(8), 740–747 (2003).
   PubMed Web of Science ®Google Scholar